Victoza vs Zepbound: Daily GLP-1 vs Dual Agonist

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub — where GLP-1 comparisons are grounded in mechanism, evidence, and the genetics that shape each metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with the manufacturers of the products reviewed.

Victoza represents one of the earliest daily GLP-1 agonists; Zepbound is among the newest dual-agonist arrivals. Comparing liraglutide with tirzepatide is really a comparison across a generational leap in incretin design. This review covers receptor action, approved use, trial evidence, safety, and cost as of April 2026 — before turning to the genetic biology both compounds share.

A first-generation daily GLP-1 meets a dual-agonist newcomer

Zepbound (tirzepatide, Eli Lilly) is a GIP/GLP-1 dual agonist. Victoza (liraglutide, Novo Nordisk) is a GLP-1-selective receptor agonist. Across the wider category, tirzepatide is a dual agonist; semaglutide, liraglutide, and dulaglutide are GLP-1-selective; and retatrutide is an investigational GLP-1/GIP/glucagon triple agonist not FDA-approved as of April 2026. All engage the GLP-1 receptor and modulate gastric emptying, post-meal glucose, and satiety.

Diabetes roots versus weight-management design

Indication history separates them. For category context: Ozempic (semaglutide) is cleared for type 2 diabetes (2017); Wegovy (semaglutide 2.4 mg) for chronic weight management (2021); Rybelsus (oral semaglutide) for type 2 diabetes (2019); Mounjaro (tirzepatide) for type 2 diabetes (2022); Zepbound (tirzepatide) for chronic weight management (2023) and obstructive sleep apnea (2024, SURMOUNT-OSA); Trulicity (dulaglutide) for type 2 diabetes (2014); and Victoza (liraglutide) for type 2 diabetes (2010). Retatrutide is investigational and not FDA-approved.

What the LEAD and SURMOUNT programs measured

The evidence tracks the molecules: STEP (semaglutide, weight), SUSTAIN and SELECT (semaglutide, diabetes and cardiovascular), SURMOUNT and SURPASS (tirzepatide, weight and diabetes), SURMOUNT-OSA (tirzepatide, sleep apnea), LEAD and LEADER (liraglutide), and AWARD (dulaglutide). Direct comparisons exist for some pairings — SUSTAIN 7 (semaglutide 1 mg vs dulaglutide 1.5 mg) and SURPASS-2 (tirzepatide vs semaglutide 1 mg in type 2 diabetes). Populations, doses, and endpoints differ, so read per-trial.

Side effects and the class warning

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the boxed warning for thyroid C-cell tumor risk observed in rodent studies, and all are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are most common during dose escalation. Rare serious events include pancreatitis, gallbladder events, and acute kidney injury with dehydration.

Monthly price and the coverage question

As of April 2026, U.S. list prices across the FDA-approved brands range roughly $815 to $1,620 per month (manufacturer published pricing). Actual out-of-pocket cost turns on insurance coverage, the FDA indication written on the prescription, manufacturer savings-card eligibility, and whether a compounded alternative is available through a licensed compounding pathway.

Shared biology beneath very different molecules

Despite the generational gap, the upstream genetics overlap. Variants in FTO (fat-mass and obesity-associated gene; appetite and adiposity set-point), GLP1R (encodes the GLP-1 receptor both compounds engage), MC4R (melanocortin receptor central to energy balance), and TCF7L2 (linked to glucose homeostasis and GLP-1 secretion) map the biology a prescription lands in. They are pathway-level and do not predict response to liraglutide, tirzepatide, or any single molecule.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols; it does not sell, distribute, or prescribe liraglutide. Whichever GLP-1 pathway compound your provider discusses, the genetic architecture is the same. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your baseline GLP-1 and energy-balance biology. That is the test before you invest approach.

Related reading on PlexusDx: Oral Zepbound, Telehealth Zepbound, Where to Buy Zepbound, Zepbound BMI.

Disclaimer: This is educational content. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and does not sell, prescribe, or recommend liraglutide. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology: take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

How does Zepbound's action differ from Victoza's?

Zepbound (tirzepatide) is a GIP/GLP-1 dual agonist that engages two incretin receptors, while Victoza (liraglutide) is GLP-1-selective. Dosing frequency also differs — Victoza is daily, tirzepatide products are weekly — and half-life varies, all of which shapes how each is administered and titrated over time.

Does one produce more weight loss than the other?

Direct liraglutide-versus-tirzepatide weight data is limited. SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes and showed larger mean weight reduction with tirzepatide there; weight-management programs used different endpoints. Individual response varies, so review specifics with a healthcare provider.

Will genetics tell me which molecule to pick?

No. The Precision Peptide Genetic Test does not predict response to Victoza, Zepbound, or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — context that applies across both molecules regardless of which is prescribed.

Are the safety concerns different between them?

Broadly similar across the class: gastrointestinal symptoms are most common and peak during dose escalation, and both carry the boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis and gallbladder disease — discuss your full history with a provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.